Biosplice joined the Unicorn Club on April 15, 2021, after raising a $120 million Series D funding round, marking a key milestone in its pursuit of advanced RNA-based therapeutics. Headquartered in San Diego, California, United States, the company develops therapies that modulate alternative splicing to treat diseases like osteoarthritis, cancer, neurological disorders, and diabetes.
Its platform targets CLK/DYRK family kinases to influence tissue-specific RNA splice-site selection, addressing the root causes of disease at the molecular level. Biosplice aims to restore health through precision therapies that harness the body’s natural splicing mechanisms to modify and reverse disease.
Keep reading to learn how Biosplice became a $12B biotechnology leader pioneering RNA splicing therapies.
What Is Biosplice and What Does It Do?
Founded in 2008, Biosplice Therapeutics (formerly known as Samumed) focuses on developing small-molecule therapeutics that regulate alternative RNA splicing. The company’s approach enables the restoration of normal cellular function in diseases where splicing errors drive pathology.
Its drug pipeline includes clinical programs for osteoarthritis, oncology, and neurodegenerative disorders, with ongoing research into metabolic and regenerative applications. By integrating biochemistry, data science, and clinical trials, Biosplice aims to redefine the treatment of chronic and degenerative diseases at the genetic level.
How Much Funding Has Biosplice Raised?
1. Series D Round
- Amount Raised: $120 million
- Date: April 15, 2021
- Valuation: $12 billion (as of February 8, 2022)
- Lead Investors: SymBiosis, Sands Capital Ventures
- Purpose: Advance late-stage clinical trials and expand the R&D pipeline in splicing-modulation therapeutics
2. Earlier Rounds (Seed to Series C)
- Cumulative Funding: ~$658 million
- Key Investors: Polaris Partners, Arch Venture Partners, and others
- Purpose: Develop a core splicing platform, clinical studies, and therapeutic expansion
Total Funding Raised: ~$778 million
Latest Funding Date: April 15, 2021
Latest Known Valuation: ~$12 billion
Employee Count: 175 (as of December 31, 2022)
Key Investors
1. SymBiosis
- Details: Investment firm focused on supporting biotech and healthcare companies advancing next-generation therapeutics.
- Focus Areas: Precision medicine, life sciences, and RNA-based therapies.
2. Sands Capital Ventures
- Details: Growth-stage investment firm backing companies driving scientific and technological innovation.
- Focus Areas: Biotechnology, healthcare, and transformative research platforms.
3. Polaris Partners
- Details: Venture capital firm investing in early and growth-stage healthcare companies.
- Focus Areas: Therapeutics, diagnostics, and digital health innovation.
Where Is Biosplice’s Headquarters?
Biosplice is headquartered in San Diego, California, United States, housing its research, clinical development, and operational teams focused on RNA splicing–based therapeutics.
What’s Next for Biosplice?
Biosplice is advancing multiple late-stage clinical programs in osteoarthritis and oncology, with plans to expand its pipeline into metabolic and neurological disorders. The company continues to invest in its RNA splicing platform, enabling broader applications in regenerative medicine and disease prevention.
With strong investor backing and a $12B valuation, Biosplice is positioned to lead the next wave of RNA-targeted therapeutics focused on disease reversal and tissue regeneration.
Get Investor & Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Biosplice. Discover insights into biotechnology, RNA therapeutics, and precision medicine startups that are transforming healthcare innovation.
Sign up for Free on TexAu to access real-time investor and funding intelligence.
